Deal Ends Today·Save 35% annual plan
Inhaled COPD therapyReviewed for 2026 plan year

Does Humana Cover Trelegy?

The verdict

Covered on most plans

Humana covers Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) on the vast majority of its Medicare Part D and Medicare Advantage formularies as a brand maintenance inhaler for COPD and asthma. Trelegy is brand-only with no generic, so coverage does not hinge on generic substitution — some Humana plans apply prior authorization or step therapy requiring a trial of a cheaper inhaler first. The 2026 $2,100 Part D out-of-pocket cap limits total annual exposure for Medicare enrollees.

MedicareCovered
CommercialCovered
See the difference

Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Humana using your member ID.

Reviewed for 2026
Checked against the active plan year
Sourced from formularies
Humana drug lists + CMS guidance
Updated as rules change
Coverage and prior-auth criteria shift often
Verify before you decide
Informational only — not insurance advice

Key facts

  • Humana is one of the largest Medicare Part D and Medicare Advantage sponsors in the US, and Trelegy appears on the vast majority of its Part D formularies.

    CMS Medicare Part D enrollment data; Humana formulary disclosures

  • Trelegy Ellipta is brand-only — no FDA-approved generic exists as of 2026 — so coverage turns on PA or step therapy rather than generic substitution.

    FDA drug labeling, Trelegy Ellipta

  • The 2026 Medicare Part D $2,100 beneficiary OOP cap limits annual out-of-pocket drug spending, including Trelegy, for all Medicare Part D enrollees.

    CMS, Medicare Part D 2026 benefit parameters

Plan types

Medicare vs. commercial coverage

Whether Humana covers Trelegy depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.

Medicare

Part D & Advantage plans

Covered

Humana is one of the largest Medicare Part D and Medicare Advantage sponsors in the US. Trelegy Ellipta is covered on the vast majority of Humana Part D plans as a brand maintenance inhaler for COPD and asthma. No generic exists, so there is no generic-substitution tier edit. Some Humana Part D plans apply prior authorization or a step-therapy requirement to trial a simpler inhaler first. The 2026 Medicare Part D $2,100 out-of-pocket cap applies. Verify PA and step-therapy requirements on the specific Humana plan formulary or at humana.com drug lookup.

Commercial / Employer

Group & marketplace plans

Covered

Humana commercial/employer plans cover Trelegy Ellipta as a brand maintenance inhaler, subject to tier and possible prior authorization or step therapy. Humana's commercial book is smaller relative to its Medicare footprint, but coverage is generally available where Humana offers commercial plans. ACA/individual plans offered by Humana in select markets also cover Trelegy at the brand tier with possible step therapy. Medicaid managed-care plans operated by Humana cover Trelegy per state PDL, with prior authorization and step therapy common for a brand-only triple-therapy inhaler. Verify on the Humana drug lookup or call member services.

Prior authorization

The 3 boxes you must tick to get approved

Commercial plans that will consider Trelegy require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.

Requirements you meet0 / 3

Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.

What you'll pay

Your cost, three ways

What Trelegy actually costs you swings enormously depending on how it's covered. Here's the realistic range.

No coverage

Paying cash

~$802–$918 per inhaler (30-day supply)

List price with no coverage — before any manufacturer savings card.

PA approved

With coverage

Varies by Humana plan tier — confirm on the Humana drug lookup. Medicare Part D cost-share is subject to the 2026 $2,100 out-of-pocket cap.

Typical monthly copay once prior authorization is approved.

Lowest cost

Bridge program

GSK (Trelegy manufacturer) offers the myGSK Assistance Program for eligible uninsured and underinsured patients. Verify eligibility at gsk.com.

Reduced copay through the assistance program, where eligible.

All cost figures are estimates. No generic alternative exists for Trelegy. Actual cost-share depends on plan tier, deductible status, and pharmacy. Verify on the Humana drug lookup at humana.com or call Humana member services.

Do it yourself

Check YOUR exact coverage in 3 steps

General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.

  1. 1

    Use the Humana drug lookup tool

    Go to humana.com and use the 'Find a Drug' or formulary tool. Enter 'Trelegy Ellipta,' select your specific Humana plan, and review the tier, prior authorization status, and any step-therapy requirements.

  2. 2

    Call Humana member services

    Call the phone number on the back of your Humana member ID card and ask: Is Trelegy on my formulary? Is prior authorization or step therapy required? What is my expected cost-share per 30-day supply?

  3. 3

    Ask your prescriber to submit a PA request if required

    If your Humana plan requires prior authorization or step-therapy documentation, your prescriber can submit clinical notes confirming your COPD or asthma diagnosis and any prior inhaler history directly to Humana. Approvals generally process within a few business days.

If it's denied

Options if Humana won't cover Trelegy

A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.

Anoro Ellipta (umeclidinium/vilanterol)

Dual-agent LABA/LAMA without an ICS; may be on a lower tier on Humana plans where triple therapy is not yet documented as necessary.

Breztri Aerosphere (budesonide/glycopyrrolate/formoterol)

Another brand triple-therapy COPD inhaler; compare tier placement with Trelegy on your Humana plan formulary before switching.

Generic fluticasone-salmeterol (ICS/LABA)

A generic dual-agent ICS/LABA combination; widely covered on Humana Part D at a preferred tier — may serve as the step-therapy option if Humana requires a simpler inhaler trial first.

These options are listed for information only — your own clinician decides what is appropriate for you.

Frequently Asked Questions

Humana covers Trelegy Ellipta on the vast majority of its Medicare Part D and Medicare Advantage formularies. Industry data shows over 96% of Part D plans list Trelegy; Humana is no exception as one of the largest Part D sponsors. The coverage variable is whether your specific plan applies prior authorization or step therapy. Verify on the Humana drug lookup or call member services to confirm your plan's PA requirements and tier placement.

No. Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is brand-only — no FDA-approved generic exists as of 2026. This is a key difference from Symbicort, where Humana Part D plans favor a lower-cost generic. Because no generic Trelegy exists, Humana cannot substitute one, and any step-therapy requirement would involve a different, simpler inhaler — not a Trelegy generic.

Yes. The 2026 Medicare Part D $2,100 beneficiary out-of-pocket cap applies to covered drugs including Trelegy on Humana Part D and Medicare Advantage plans. Once your OOP spending hits $2,100 in 2026, you pay $0 for covered Part D drugs for the remainder of the year. This cap is a significant protection given Trelegy's $802–$918 cash price. Cost-share before reaching the cap depends on your specific Humana plan's tier for Trelegy.

Yes — the coverage logic is structurally opposite. Symbicort has a generic (budesonide/formoterol) that Humana Part D plans favor at a lower tier, and brand Symbicort is frequently non-preferred or not covered on Part D. Trelegy is brand-only with no generic, so Humana's Part D coverage of Trelegy hinges on prior authorization or step therapy, not on whether you take the generic. These are the two contrasting inhaler-coverage patterns within Humana.

Trelegy was selected by CMS for Medicare price negotiation but in a later cohort than the first 10 drugs whose negotiated prices took effect in 2026. There is no government-negotiated Trelegy price in effect in 2026 for Humana Medicare plans. Do not assume any negotiated-price discount applies. Verify the current effective year against the CMS selected-drug list before expecting any savings beyond the standard 2026 OOP cap.

This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Humana before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation.